Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on VolitionRX. The associated price target remains the same with $2.50.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yi Chen has given his Buy rating due to a combination of factors including VolitionRX’s recent strategic partnership and the potential for future growth. The company has entered into a significant agreement with Werfen, a leader in in vitro diagnostics, to out-license its Nu.Q NETs assay. This partnership is expected to leverage Werfen’s expertise and infrastructure, potentially leading to increased revenue through upfront and milestone payments, as well as future royalties.
Additionally, VolitionRX’s business model, which focuses on licensing revenue and consumable sales, is poised to benefit from expanding interest in its Nu.Q platform for cancer diagnostics. The company’s valuation, supported by a discounted cash flow analysis, suggests a price target of $2.50 per share. However, there are risks such as potential failures in clinical development and securing license agreements, which investors should consider.